Meso-Erythritol is an investigational drug.
There have been 22 clinical trials for Meso-Erythritol.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2018.
The most common disease conditions in clinical trials are Mesothelioma, Malignant, Mesothelioma, and Pancreatic Neoplasms. The leading clinical trial sponsors are Stony Brook University, Hrain Biotechnology Co., Ltd., and Hrain Biotechnology Co.,Ltd.
There are fifteen US patents protecting this investigational drug and five hundred and twenty-seven international patents.